Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navigating the Difficulties of Nutrition During Cancer Care as a Nurse

April 26, 2025
By Claudia Aguilar Clancy, RN, FNP-C
News
Video
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

“Food is powerful, and [patients] need fuel,” said Claudia Aguilar Clancy, RN, FNP-C, about ensuring patients receive the nutrition they require during cancer treatment.

Claudia Aguilar Clancy, RN, FNP-C, stated that addressing the nutritional needs of patients with various types of cancer can be difficult because it depends on several things, such as where the tumor developed and whether the patient requires a feeding tube.

During a conversation with CancerNetwork® at the 2025 Oncology Nursing Society Congress, Clancy, a nurse practitioner at Texas Oncology, discussed the complexities of helping patients meet their dietary and nutritional needs during cancer care. For those who have to use a feeding tube, soft foods and pureed foods are commonly used; Clancy stated that there is a long list of high-protein and soft food options that she shows her patients so they receive “the best fuel possible.”

Additionally, the type of treatment that a patient receives factors into what they can and cannot eat. If a patient receives radiation therapy directed at the gastrointestinal tract, Clancy will not serve that patient foods with high amounts of fiber because it may lead to more diarrhea or nausea.

The goal is not only to supply food that mitigates adverse effects (AEs) but also to provide a patient with the strength to get through their treatments.


Transcript:

I love my head and neck population. They are challenging, and they’re unique because it depends on where the tumor starts and it depends on where the feeding tube is going to go. Is it going to be in the stomach? Is it going to be in the jejunum, [also known as] the J-tube? If they can eat some [food], normally we assess, “OK, do they have a feeding tube? Can they eat orally?” If they cannot, then that’s when the formulas are obtained and [they get] soft foods and pureed foods. I give them a big list of all those [items] that are high protein but soft. They’re getting the best fuel possible.

Then we have our patients who don’t have a feeding tube, and those patients can eat. During radiation, depending on where the radiation is, if it’s a [gastrointestinal] tract radiation location, then we have to think about lower-fiber [foods] even though fiber is good, but at that particular time, it can cause more diarrhea and more of those [AEs] that we don’t want them to have. It could also cause a little more nausea and things like that.

We have to see what the diagnosis is to tailor the nutrition part of it so that they can be successful and have low [AEs] because of food but also have food that is going to help them get through the radiation. Food is powerful, and they need fuel. It’s a challenge because at that time, they don’t want to eat, but they have to eat.

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Related Content
Advertisement

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma

Russ Conroy
July 16th 2025
Article

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

Kristi Rosa
July 13th 2025
Article

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma

Roman Fabbricatore
July 10th 2025
Article

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.


Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Russ Conroy
July 10th 2025
Article

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Related Content
Advertisement

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma

Russ Conroy
July 16th 2025
Article

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

Kristi Rosa
July 13th 2025
Article

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma

Roman Fabbricatore
July 10th 2025
Article

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.


Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Russ Conroy
July 10th 2025
Article

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.